BRIEF-TScan Therapeutics Announces 30% Workforce Reduction, Cash Runway Extension

Reuters

Nov 03, 2025

BRIEF-TScan <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces 30% Workforce Reduction, Cash Runway Extension

Nov 3 (Reuters) - TScan Therapeutics Inc TCRX.O:

TSCAN THERAPEUTICS REACHES AGREEMENT WITH FDA ON PIVOTAL STUDY DESIGN FOR TSC-101 AND ANNOUNCES STRATEGIC PRIORITIZATION TO ADVANCE TSC-101 AND EXTEND CASH RUNWAY INTO H2 2027
TSCAN THERAPEUTICS INC - ANNOUNCES 30% WORKFORCE REDUCTION AND CASH RUNWAY EXTENSION
TSCAN THERAPEUTICS INC: STRATEGIC PRIORITIZATION EXTENDS CASH RUNWAY INTO H2 2027
TSCAN THERAPEUTICS INC - EXPECTS $45 MILLION ANNUAL SAVINGS FROM STRATEGIC PRIORITIZATION
TSCAN THERAPEUTICS INC - TO BEGIN TSC-101 PIVOTAL TRIAL IN Q2 2026
TSCAN: PAUSED FURTHER ENROLLMENT OF PATIENTS WITH MULTIPLEX TCR-T THERAPY TO PRIORITIZE HEME DEVELOPMENT; REITERATES PLANNED DATA READOUT IN Q1 2026

Source text: ID:nGNX40nw9W

Further company coverage: TCRX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580824292"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580824292\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580824292?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 19:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580824292","market":"fut","top_or_hot":-1,"title":"BRIEF-TScan Therapeutics Announces 30% Workforce Reduction, Cash Runway Extension","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-TScan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces 30% Workforce Reduction, Cash Runway Extension</title></head><body><p><span>Nov 3 (Reuters)</span><span> - </span>TScan Therapeutics Inc <span>TCRX.O</span>:</p><ul><li><p>TSCAN THERAPEUTICS REACHES AGREEMENT WITH FDA ON PIVOTAL STUDY DESIGN FOR TSC-101 AND ANNOUNCES STRATEGIC PRIORITIZATION TO ADVANCE TSC-101 AND EXTEND CASH RUNWAY INTO H2 2027</p></li><li><p>TSCAN THERAPEUTICS INC - ANNOUNCES 30% WORKFORCE REDUCTION AND CASH RUNWAY EXTENSION</p></li><li><p>TSCAN THERAPEUTICS INC: STRATEGIC PRIORITIZATION EXTENDS CASH RUNWAY INTO H2 2027</p></li><li><p>TSCAN THERAPEUTICS INC - EXPECTS $45 MILLION ANNUAL SAVINGS FROM STRATEGIC PRIORITIZATION</p></li><li><p>TSCAN THERAPEUTICS INC - TO BEGIN TSC-101 PIVOTAL TRIAL IN <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>TSCAN: PAUSED FURTHER ENROLLMENT OF PATIENTS WITH MULTIPLEX TCR-T THERAPY TO PRIORITIZE HEME DEVELOPMENT; REITERATES PLANNED DATA READOUT IN Q1 2026</p></li></ul><p>Source text: <span>ID:nGNX40nw9W</span></p><p>Further company coverage: <span>TCRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-TScan Therapeutics Announces 30% Workforce Reduction, Cash Runway Extension</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-TScan Therapeutics Announces 30% Workforce Reduction, Cash Runway Extension\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-03 19:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-TScan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces 30% Workforce Reduction, Cash Runway Extension</title></head><body><p><span>Nov 3 (Reuters)</span><span> - </span>TScan Therapeutics Inc <span>TCRX.O</span>:</p><ul><li><p>TSCAN THERAPEUTICS REACHES AGREEMENT WITH FDA ON PIVOTAL STUDY DESIGN FOR TSC-101 AND ANNOUNCES STRATEGIC PRIORITIZATION TO ADVANCE TSC-101 AND EXTEND CASH RUNWAY INTO H2 2027</p></li><li><p>TSCAN THERAPEUTICS INC - ANNOUNCES 30% WORKFORCE REDUCTION AND CASH RUNWAY EXTENSION</p></li><li><p>TSCAN THERAPEUTICS INC: STRATEGIC PRIORITIZATION EXTENDS CASH RUNWAY INTO H2 2027</p></li><li><p>TSCAN THERAPEUTICS INC - EXPECTS $45 MILLION ANNUAL SAVINGS FROM STRATEGIC PRIORITIZATION</p></li><li><p>TSCAN THERAPEUTICS INC - TO BEGIN TSC-101 PIVOTAL TRIAL IN <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>TSCAN: PAUSED FURTHER ENROLLMENT OF PATIENTS WITH MULTIPLEX TCR-T THERAPY TO PRIORITIZE HEME DEVELOPMENT; REITERATES PLANNED DATA READOUT IN Q1 2026</p></li></ul><p>Source text: <span>ID:nGNX40nw9W</span></p><p>Further company coverage: <span>TCRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA6VBLYR:1","article_id":"2580824292","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580824292","pubTimestamp":1762170000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-TScan Therapeutics Announces 30% Workforce Reduction, Cash Runway ExtensionNov 3 (Reuters) - TScan Therapeutics Inc TCRX.O:TSCAN THERAPEUTICS REACHES AGREEMENT WITH FDA ON PIVOTAL STUDY DESIGN F","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TCRX":"Tscan Therapeutics, Inc.","BK4539":"次新股"},"translate_title":"简介-TScan Therapeutics宣布裁员30%并延长现金跑道","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TCRX":0.9},"content_text":"BRIEF-TScan Therapeutics Announces 30% Workforce Reduction, Cash Runway ExtensionNov 3 (Reuters) - TScan Therapeutics Inc TCRX.O:TSCAN THERAPEUTICS REACHES AGREEMENT WITH FDA ON PIVOTAL STUDY DESIGN FOR TSC-101 AND ANNOUNCES STRATEGIC PRIORITIZATION TO ADVANCE TSC-101 AND EXTEND CASH RUNWAY INTO H2 2027TSCAN THERAPEUTICS INC - ANNOUNCES 30% WORKFORCE REDUCTION AND CASH RUNWAY EXTENSIONTSCAN THERAPEUTICS INC: STRATEGIC PRIORITIZATION EXTENDS CASH RUNWAY INTO H2 2027TSCAN THERAPEUTICS INC - EXPECTS $45 MILLION ANNUAL SAVINGS FROM STRATEGIC PRIORITIZATIONTSCAN THERAPEUTICS INC - TO BEGIN TSC-101 PIVOTAL TRIAL IN Q2 2026TSCAN: PAUSED FURTHER ENROLLMENT OF PATIENTS WITH MULTIPLEX TCR-T THERAPY TO PRIORITIZE HEME DEVELOPMENT; REITERATES PLANNED DATA READOUT IN Q1 2026Source text: ID:nGNX40nw9WFurther company coverage: TCRX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}